Bevacizumab, a monoclonal antibody that targets the vascular endothelial growth factor (VEGF), has demonstrated benefits in combination with chemotherapy for certain patients with metastatic cervical cancer (Tewari et al., 2014; Tewari et al., 2017). The gene discussed is VEGFA; the disease is cervical cancer.